6-K: Report of foreign issuer [Rules 13a-16 and 15d-16]
Published on
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington. D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR I5d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2004
Novogen Limited
(Translation of registrant's name into English)
140 Wicks Road, North Ryde, NSW, 2113, Australia
(Address of principal executive office)
[Indicate by check mark whether the registrant files or will file
annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F v Form 40-F
[Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934. Yes No
[If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2 (b):
82- ________________ .1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Novogen Limited
(Registrant)
Date 4 June,2004 By /s/Ronald Lea Erratt Company Secretary
ASX RELEASE
4 June 2004
Rule 3.19A.2
Appendix 3Y
Change of Director's Interest Notice
Information or documents not available now must
be given to ASX as soon as available.
Information and documents given to ASX become ASX's
property and may be made public.
Introduced 30/9/2001.
Name of entity: NOVOGEN LIMITED
ABN: 37 063 259 754
We (the entity) give ASX the following
information under listing rule 3.19A.2
and as agent for the director for the purposes
of section 205G of the Corporations Act.
Name of Director GRAHAM EDMUND KELLY
Date of last notice 14 November, 2003
Part 1 - Change of directors relevant interests
in securities
In the case of a trust, this includes interests
in the trust made available by the responsible
entity of the trust
Direct or indirect interest
Direct and indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
As a director of: Bende Holdings Pty Ltd;
Coolawin Road Pty Ltd; and Phytose Corporation Pty Ltd
Date of change Completed
3 June, 2004
No. of securities held prior to change
1,104,600 personally; 6,505,538 in Bende Holdings Pty Ltd;
513,654 in Coolawin Road Pty Ltd; and
7,000 in Phytose Corporation Pty Ltd
Class
Ordinary
Number acquired
nil
Number disposed
20,000 as a Director of Bende Holdings Pty Ltd;
100 personally
Value/Consideration
Note: If consideration is non-cash, provide
details and estimated valuation
Sold at an average price per share of $5.0578
No. of securities held after change
1,104,500 personally; 6,485,538 in Bende Holdings
Pty Ltd; 513,654 in Coolawin Road Pty Ltd;
and 7,000 in Phytose Corporation Pty Ltd
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in buy-back
On market trade
Part 2 Change of director's interests in contracts
Detail of contract
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which interest
related prior to change
Note: Details are only required for a contract
in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash,
provide details and an estimated valuation
Interest after change
4 June, 2004
CONTACT: US-Australia: Mr Christopher Naughton,
CEO, Marshall Edwards, Inc., + 61.2.9878 0088